Ask AI

mTNBC Practice Readiness: Applying Current Standards and Interpreting Emerging First-line TROP2 ADC Evidence for Immunotherapy-Ineligible Patients

Increase your competence in applying current standards of care and emerging first-line TROP2-directed ADC therapies for immunotherapy-ineligible patients with metastatic triple-negative breast cancer to individualize treatment selection and sequencing, prevent and manage treatment-related toxicities, and counsel patients through a podcast, a certified on-demand webcast with accompanying downloadable slides, certified text modules, a certified interactive case challenge, and expert-written ClinicalThought commentaries.

Share

Program Content

Activities

TROP2 ADCs in TNBC
Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC
Podcast
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2026

Activities

TROP2 ADCs in mTNBC
mTNBC Practice Readiness: Applying Current Standards and Interpreting Emerging First-line TROP2 ADC Evidence for Immunotherapy-Ineligible Patients
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 08, 2026

Activities

1L TROP2 ADC Evidence
mTNBC Practice Readiness: Applying Current Standards and Interpreting Emerging First-line TROP2 ADC Evidence for Immunotherapy-Ineligible Patients
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 13, 2026

Expires: April 12, 2027

Activities

1L TROP2 in mTNBC
Integrating Emerging First-line Evidence Into Treatment of Immunotherapy-Ineligible mTNBC
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2026

Expires: April 22, 2027

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.